AKBA

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Akebia Therapeutics (AKBA – Research Report), with a price target of $1.25. The company's shares closed last Thursday at $0.41, close to its 52-week low of $0.30. According to TipRanks.com, Arce is a 4-star analyst with an average return of 9.0% and a 39.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals. Currently, the analyst consensus on Akebia Therapeutics is a Hold with an average price target of $1.63.
https://www.tipranks.com/news/blurbs/h-c-wainwright-maintains-a-hold-rating-on-akebia-therapeutics-akba-2?utm_source=advfn.com&utm_medium=referral